SUPPORT AGREEMENTSupport Agreement • February 22nd, 2024 • Foresite Capital Fund V, L.P. • Pharmaceutical preparations • Delaware
This SUPPORT AGREEMENT (“Agreement”), dated as of February 16, 2024, is made by and among XOMA Corporation, a Delaware corporation (“Parent”), XRA 1 Corp., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and the undersigned holder (“Stockholder”) of shares of common stock, par value $0.0001 per share (the “Company Common Stock”), of Kinnate Biopharma Inc., a Delaware corporation (the “Company”). Capitalized terms used herein and not defined shall have the meanings ascribed to them in the Merger Agreement (as defined below).
